These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 34502108)
21. Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art. Consiglieri G; Bernardo ME; Brunetti-Pierri N; Aiuti A Hematol Oncol Clin North Am; 2022 Aug; 36(4):865-878. PubMed ID: 35773049 [TBL] [Abstract][Full Text] [Related]
22. Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses. Muenzer J; Ho C; Lau H; Dant M; Fuller M; Boulos N; Dickson P; Ellinwood NM; Jones SA; Zanelli E; O'Neill C Mol Genet Metab; 2024 Aug; 142(4):108535. PubMed ID: 39018614 [TBL] [Abstract][Full Text] [Related]
30. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery. McIntyre C; Derrick-Roberts AL; Byers S; Anson DS J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946 [TBL] [Abstract][Full Text] [Related]
31. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy. Fecarotta S; Gasperini S; Parenti G Ital J Pediatr; 2018 Nov; 44(Suppl 2):124. PubMed ID: 30442204 [TBL] [Abstract][Full Text] [Related]
32. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts]. Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532 [TBL] [Abstract][Full Text] [Related]
33. Current and Emerging Therapies for Mucopolysaccharidoses. Lagler FB Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968 [TBL] [Abstract][Full Text] [Related]
38. Substrate reduction therapies for mucopolysaccharidoses. Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626 [TBL] [Abstract][Full Text] [Related]
39. Therapies for neurological disease in the mucopolysaccharidoses. Anson DS; McIntyre C; Byers S Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356 [TBL] [Abstract][Full Text] [Related]
40. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]